Interestingly, various drugs used to clinically treat MS such as recombinant IFNβ, glatiramer acetate and natalizumab suppress NLRP3 mRNA expression, and decrease IL-1β in the blood and CSF of MS patients (160–162). Here, NLRP3 is linked to myeloid sarcoma.